Acasti Pharma Inc. (ACST) Company Long-Term Loans and Borrowings

Public company logo of acastipharma.com (ACST)

The asset value of Acasti Pharma (ACST) tracked on this chart stands at 0.00, while the market potential for therapeutic agents to combat neurological and skin pain remains significant. The business relies on creating new modifications of familiar compounds to improve their bioavailability in treating rare pathologies. The company's prospects are based on developing unique delivery methods for small molecules in cardiology.

ACST Acasti Pharma Inc: Company Long-Term Debts in the range 07/04/2022 - 10/28/2024

Acasti Pharma Inc. (ACST) - metric breakdowns and financial figures

- price and consensus price forecast:
Stock Price Acasti Pharma Inc|ACST - Price Target Chart
- market capitalization data:
Market Value Acasti Pharma|ACST - Real Price to Acquire Entire Company
- book capitalization data:
Book Price of a Share Acasti Pharma|ACST - Book Capitalization|Market Capitalization to Book Value Ratio acastipharma.com|ACST - Company Total Assets
- debt and liquidity data:
Total Debt to Equity Ratio Acasti Pharma|ACST - Long-Term Debt to Capital|Short-Term Debt to Capital Acasti Pharma Inc|ACST - Company Debts|Debts to Net Assets Acasti Pharma|ACST - Company Long-Term Liabilities|Amount of Current Liabilities Acasti Pharma
General company analysis:ACST - Acasti Pharma
Original product of Acasti Pharma Inc.

Developing drug delivery systems for neurological pain requires significant capital to conduct late-stage clinical trials. By analyzing the corporation's long-term loans and borrowings, an investor assesses the total liabilities with a maturity of more than one year. This metric measures the long-term debt load, allowing for the determination of default risk in a rising rate environment. A stable debt level confirms the financial stability of Acasti Pharma (ACST). The current liquidity reserve minimizes dependence on external borrowings.

Competitors of Acasti Pharma

regeneron.com - Company Long-Term Debts|Company Long-Term Debt iRhythm (IRTC)|Lantheus Holdings (LNTH) - Company Long-Term Loans and Borrowings|MLYS - Company Long-Term Liabilities|HeartFlow, Inc. (HTFL) - Amount of Long-Term Liabilities|KMTS (Kestra Medical Technologies) - Company Long-Term Debts|Company Long-Term Debts esperion.com|Company Long-Term Debts AMRN (Amarin)|Company Long-Term Liabilities anteristech.com (AVR)|Company Long-Term Debts TNYA (Tenaya Therapeutics, Inc.)|CVRx Inc - Company Long-Term Debts|Company Long-Term Debt MIST (Milestone Pharmaceuticals)|Cardiol Therapeutics (CRDL) - Long-Term Debt Volume|BEAT - Company Long-Term Liabilities|Tenax Therapeutics Inc. (TENX) - Amount of Long-Term Liabilities|ADGM: Company Long-Term Debts|Long-Term Debt Volume BioCardia Inc (BCDA)|Catheter Precision (VTAK) - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings ABIO (arcabio.com)|Aerovate Therapeutics, Inc. (AVTE) - Company Long-Term Debt|Long-Term Liabilities Verve Therapeutics Inc. VERV|Company Long-Term Debts Windtree (WINT)